281 related articles for article (PubMed ID: 29624748)
1. Nivolumab maintenance after salvage autologous stem cell transplantation results in long-term remission in multiple relapsed primary CNS lymphoma.
Terziev D; Hutter B; Klink B; Stenzinger A; Stögbauer F; Glimm H; Fröhling S; Wickenhauser C; Jordan K; Hurtz HJ; Müller LP; Rüssel J; Weber T
Eur J Haematol; 2018 Jul; 101(1):115-118. PubMed ID: 29624748
[TBL] [Abstract][Full Text] [Related]
2. Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single-centre experience and literature review.
Bojic M; Berghoff AS; Troch M; Agis H; Sperr WR; Widhalm G; Wöhrer A; Kalhs P; Preusser M; Rabitsch W
Eur J Haematol; 2015 Jul; 95(1):75-82. PubMed ID: 25546348
[TBL] [Abstract][Full Text] [Related]
3. Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation.
Choi MK; Kang ES; Kim DW; Ko YH; Seok H; Park JH; Pyo DH; Hoon Lim D; Kim SJ; Kim WS
Int J Hematol; 2013 Sep; 98(3):346-54. PubMed ID: 23868695
[TBL] [Abstract][Full Text] [Related]
4. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group.
Kasenda B; Ihorst G; Schroers R; Korfel A; Schmidt-Wolf I; Egerer G; von Baumgarten L; Röth A; Bloehdorn J; Möhle R; Binder M; Keller U; Lamprecht M; Pfreundschuh M; Valk E; Fricker H; Schorb E; Fritsch K; Finke J; Illerhaus G
Leukemia; 2017 Dec; 31(12):2623-2629. PubMed ID: 28559537
[TBL] [Abstract][Full Text] [Related]
5. Treatment Options for Recurrent Primary CNS Lymphoma.
Kaulen LD; Baehring JM
Curr Treat Options Oncol; 2022 Nov; 23(11):1548-1565. PubMed ID: 36205806
[TBL] [Abstract][Full Text] [Related]
6. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
7. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.
Nayak L; Iwamoto FM; LaCasce A; Mukundan S; Roemer MGM; Chapuy B; Armand P; Rodig SJ; Shipp MA
Blood; 2017 Jun; 129(23):3071-3073. PubMed ID: 28356247
[TBL] [Abstract][Full Text] [Related]
8. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
[TBL] [Abstract][Full Text] [Related]
9. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
DeFilipp Z; Li S; El-Jawahri A; Armand P; Nayak L; Wang N; Batchelor TT; Chen YB
Cancer; 2017 Aug; 123(16):3073-3079. PubMed ID: 28369839
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic management of refractory or relapsed primary central nervous system lymphomas.
Reni M; Ferreri AJ
Ann Hematol; 2001; 80 Suppl 3():B113-7. PubMed ID: 11757691
[TBL] [Abstract][Full Text] [Related]
11. High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom.
Kassam S; Chernucha E; O'Neill A; Hemmaway C; Cummins T; Montoto S; Lennard A; Adams G; Linton K; McKay P; Davies D; Rowntree C; Easdale S; Eyre TA; Marcus R; Cwynarski K; Fox CP
Bone Marrow Transplant; 2017 Sep; 52(9):1268-1272. PubMed ID: 28581466
[TBL] [Abstract][Full Text] [Related]
12. A single-center retrospective analysis of outcome measures and consolidation strategies for relapsed and refractory primary CNS lymphoma.
Bonm AV; Gibson AW; Holmberg LA; Mielcarek M; McGranahan T; Taylor LP; Graber JJ
J Neurooncol; 2021 Jan; 151(2):193-200. PubMed ID: 33398532
[TBL] [Abstract][Full Text] [Related]
13. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.
Langner-Lemercier S; Houillier C; Soussain C; Ghesquières H; Chinot O; Taillandier L; Soubeyran P; Lamy T; Morschhauser F; Benouaich-Amiel A; Ahle G; Moles-Moreau MP; Moluçon-Chabrot C; Bourquard P; Damaj G; Jardin F; Larrieu D; Gyan E; Gressin R; Jaccard A; Choquet S; Brion A; Casasnovas O; Colin P; Reman O; Tempescul A; Marolleau JP; Fabbro M; Naudet F; Hoang-Xuan K; Houot R
Neuro Oncol; 2016 Sep; 18(9):1297-303. PubMed ID: 26951382
[TBL] [Abstract][Full Text] [Related]
14. Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study.
Kasenda B; Schorb E; Fritsch K; Finke J; Illerhaus G
Ann Oncol; 2012 Oct; 23(10):2670-2675. PubMed ID: 22473593
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
Corazzelli G; Russo F; Capobianco G; Marcacci G; Della Cioppa P; Pinto A
Ann Oncol; 2006 May; 17 Suppl 4():iv18-24. PubMed ID: 16702180
[TBL] [Abstract][Full Text] [Related]
16. Advances in therapeutic strategies for primary CNS B-cell lymphomas.
Ramadan S; Radice T; Ismail A; Fiori S; Tarella C
Expert Rev Hematol; 2022 Apr; 15(4):295-304. PubMed ID: 35467473
[TBL] [Abstract][Full Text] [Related]
17. The role of upfront autologous stem cell transplantation in high-risk younger patients with primary central nervous system lymphoma.
Cho H; Chang JH; Kim YR; Kim SJ; Chung H; Park H; Lee JY; Jang JE; Kim Y; Kim SH; Yang WI; Suh CO; Cheong JW; Min YH; Kim JS
Br J Haematol; 2016 Aug; 174(3):444-53. PubMed ID: 27018207
[TBL] [Abstract][Full Text] [Related]
18. Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide.
Welch MR; Sauter CS; Matasar MJ; Faivre G; Weaver SA; Moskowitz CH; Omuro AM
Leuk Lymphoma; 2015 Feb; 56(2):361-7. PubMed ID: 24745937
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation.
Correa DD; Braun E; Kryza-Lacombe M; Ho KW; Reiner AS; Panageas KS; Yahalom J; Sauter CS; Abrey LE; DeAngelis LM; Omuro A
J Neurooncol; 2019 Sep; 144(3):553-562. PubMed ID: 31377920
[TBL] [Abstract][Full Text] [Related]
20. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma.
Cheng T; Forsyth P; Chaudhry A; Morris D; Glück S; Russell JA; Stewart DA
Bone Marrow Transplant; 2003 Apr; 31(8):679-85. PubMed ID: 12692608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]